The general goal of this renewal proposal is to understand the biomechanical mechanism by which extracellular matrix (ECM) regulates angiogenesis during tumor development, with a specific focus on how physical interactions between capillary endothelial (CE) cells and their ECM adhesions control directional cell motility. During the last grant period, we showed that mechanical changes at the cell-ECM interface govern the direction in which cells move because local variations of physical force distributions dictate where cells will form focal adhesions (FAs) and extend new motile processes when stimulated with soluble motility factors. Analysis of this motility steering mechanism and the mechanism of FA repositioning revealed a central role for transfer of mechanical forces across transmembrane integrin receptors which elicit signaling responses that, in turn, activate additional p1 integrin receptors. Other signaling molecules, including the small GTPases, Rho and Rac, also contribute to the mechanism by which ECM influences FA location, and cells that lack the FA protein paxillin fail to exhibit spatial coupling between FA formation and lamellipodia extension. In separate studies, we discovered that an upstream regulator of Rho, p190RhoGAP, may link cytoskeletal signaling to cell motility and angiogenesis by another mechanism: this Rho inhibitor regulates the activity of the transcription factor TFII-I and thereby controls expression of the vascular endothelial growth factor (VEGF) receptor VEGFR2. Thus, the specific aims include: 1) To explore how stress- dependent activation of (31 integrin and Rho alter focal adhesion position, 2) To determine how focal adhesions govern lamellipodia positioning and directional cell migration, and 3) To analyze how cytoskeletal signaling through p190RhoGAP influences VEGFR2 gene expression. These studies will include in vitro mechanistic experiments as well as in vivo studies in a tumor angiogenesis model to determine the potential clinical relevance of our findings. Understanding the molecular basis of this mechanical signaling response that controls direction migration of capillary blood vessel cells could lead to identification of new molecular targets for therapeutic intervention in virtually all solid cancers that require continuous angiogenesis for their own growth and expansion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA045548-24
Application #
8129684
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
24
Fiscal Year
2010
Total Cost
$301,705
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Adapala, R K; Thoppil, R J; Ghosh, K et al. (2016) Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene 35:314-22
Battinelli, Elisabeth M; Markens, Beth A; Kulenthirarajan, Rajesh A et al. (2014) Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 123:101-12
Li, Wenliang; Ai, Nanping; Wang, Suming et al. (2014) GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proc Natl Acad Sci U S A 111:1521-6
Pelton, Kristine; Coticchia, Christine M; Curatolo, Adam S et al. (2014) Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol 184:2099-110
German, Alexandra E; Mammoto, Tadanori; Jiang, Elisabeth et al. (2014) Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression. J Cell Sci 127:1672-83
Ingber, Donald E; Wang, Ning; Stamenovic, Dimitrije (2014) Tensegrity, cellular biophysics, and the mechanics of living systems. Rep Prog Phys 77:046603
Roy, R; Zurakowski, D; Wischhusen, J et al. (2014) Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer 111:1772-9
Procaccia, Vera; Nakayama, Hironao; Shimizu, Akio et al. (2014) Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility. Biochem Biophys Res Commun 448:134-8
Gee, Elaine P S; YĆ¼ksel, Deniz; Stultz, Collin M et al. (2013) SLLISWD sequence in the 10FNIII domain initiates fibronectin fibrillogenesis. J Biol Chem 288:21329-40
Baek, Kwan-Hyuck; Bhang, Dongha; Zaslavsky, Alexander et al. (2013) Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest 123:4375-89

Showing the most recent 10 out of 277 publications